Gilbert & Cook Inc. Has $1.18 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 11th, 2023

Gilbert & Cook Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,637 shares of the company’s stock after purchasing an additional 414 shares during the period. Gilbert & Cook Inc.’s holdings in Johnson & Johnson were worth $1,184,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Moneta Group Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after acquiring an additional 54,326,454 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock worth $8,456,643,000 after acquiring an additional 294,671 shares during the period. Morgan Stanley lifted its holdings in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after acquiring an additional 3,849,148 shares during the period. Finally, Norges Bank bought a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $4,609,399,000. Institutional investors and hedge funds own 67.57% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $172.18 on Friday. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The company has a fifty day moving average price of $164.21 and a 200-day moving average price of $161.13. The company has a market capitalization of $447.48 billion, a P/E ratio of 34.85, a PEG ratio of 2.90 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same period in the prior year, the company posted $2.59 earnings per share. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. As a group, equities analysts expect that Johnson & Johnson will post 10.75 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.76%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Barclays increased their price objective on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research note on Monday, July 24th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They issued a “strong-buy” rating for the company. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Finally, Citigroup initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective for the company. Eight research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $171.80.

Check Out Our Latest Analysis on JNJ

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 over the last three months. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.